Literature DB >> 29103691

Immunogenicity and protective efficacy of inactivated equine influenza (H3N8) virus vaccine in murine model.

Selvaraj Pavulraj1, Nitin Virmani2, Bidhan Chandra Bera3, Alok Joshi4, Taruna Anand3, Meenakshi Virmani5, Rajendra Singh6, Raj Kumar Singh6, Bhupendra Nath Tripathi3.   

Abstract

Equine influenza viruses (EIVs) are responsible for acute contagious respiratory infection in equines and the disease remains a major threat for equine population throughout the world despite vaccination strategies in place. The present study was aimed to assess the suitability of BALB/c mice as a potential small animal model for preliminary screening of EI vaccine candidates. For this, we evaluated the immunogenicity and protective efficacy of an inactivated EIV (H3N8) vaccine in BALB/c mouse model after challenge with homologous H3N8 virus (Clade 2 virus, Florida sublineage) through serology, clinical signs, gross and histopathology lesions with grading, immunohistochemistry and virus quantification. Serological responses in immunized mice were evaluated by haemagglutination inhibition assay (HAI) and antibodies were subtyped by ELISA. The vaccine induced optimum protective antibody titre on 49 dpi along with balanced Th1/Th2 responses. Immunized mice were well protected against EIV challenge as evident by significant rise in serum antibody titre which concurred with mild clinical signs, early recovery, lower gross and histopathological lesions score, less severe intensity of viral antigen distribution, restricted virus replication in respiratory tract and less virus detection in nasal washes for short duration. The duration of the viral load was also lower and only for brief period as compared to unvaccinated challenged mice. In conclusion, induction of H3N8 specific antibody response and protection against H3N8 challenge proves that egg grown inactivated H3N8 whole virus vaccine would provide an effective intercession against H3N8 virus. In addition, BALB/c mouse can serve as an attractive tool for adjudging protective efficacy of vaccine candidates prior to final testing in equines.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Equine influenza; Mice model; Protective efficacy; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29103691     DOI: 10.1016/j.vetmic.2017.08.013

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  4 in total

Review 1.  Equine Influenza Virus and Vaccines.

Authors:  Fatai S Oladunni; Saheed Oluwasina Oseni; Luis Martinez-Sobrido; Thomas M Chambers
Journal:  Viruses       Date:  2021-08-20       Impact factor: 5.818

2.  Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines.

Authors:  Dong-Ha Lee; Eun-Bee Lee; Jong-Pil Seo; Eun-Ju Ko
Journal:  J Anim Sci Technol       Date:  2022-05-31

Review 3.  A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies.

Authors:  Raj K Singh; Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Ashok Munjal; Sandip K Khurana; Sandip Chakraborty; Yashpal S Malik; Nitin Virmani; Rajendra Singh; Bhupendra N Tripathi; Muhammad Munir; Johannes H van der Kolk
Journal:  Front Microbiol       Date:  2018-09-06       Impact factor: 5.640

4.  Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with MontanideTM Pet Gel in murine model.

Authors:  Manu Kurian Mathew; Nitin Virmani; Bidhan Chandra Bera; Taruna Anand; Ramesh Kumar; Venkataramireddy Balena; Rekha Sansanwal; Selvaraj Pavulraj; Karthik Sundaram; Meenakshi Virmani; Bhupendra Nath Tripathi
Journal:  J Vet Med Sci       Date:  2019-10-28       Impact factor: 1.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.